Effect of Speech Enhancer on Listening Effort With EEG

Sponsor
Sonova AG (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT06049199
Collaborator
Hoerzentrum Oldenburg (Other)
27
1
5.5

Study Details

Study Description

Brief Summary

In previous studies, Speech Enhancer has been shown to improve Listening Effort using a subjective method. To overcome the weakness of subjective testing, this study uses an objective measurement that has shown convincing results in previous studies addressing Listening Effort.

Condition or Disease Intervention/Treatment Phase
  • Other: Speech Enhancer
N/A

Detailed Description

The Speech Enhancer (SE) provides better speech intelligibility for soft speech while maintaining the same sound quality for loud input level.

Better speech intelligibility may also result in less listening effort in some circumstances. So there was the hope that the SE provides better speech intelligibility and less listening effort for situation with soft speech.

The SE has already been intensely and successfully investigated in early studies.

The cognitive performance on a neurophiosiological level has already been successfully investigated in a previous studies.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
27 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Assess the Effect of Speech Enhancer on Listening Effort With EEG
Anticipated Study Start Date :
Oct 16, 2023
Anticipated Primary Completion Date :
Dec 22, 2023
Anticipated Study Completion Date :
Mar 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Hearing impaired group

The hearing impaired group will compare the reference condition (SpeechEnhancer on) with the intervention condition (SpeechEnhancer off).

Other: Speech Enhancer
Speech Enhancer is an adaptive feature which increases the amplitude of speech signal when speech is detected. Speech Enhancer will be switched on and off for the Intervention

Outcome Measures

Primary Outcome Measures

  1. EEG alpha power measured during Listening Effort Task (LET) [10 weeks]

    During the LET experiment EEG data will be recorded while participants perform the Adaptive CAtegorical Listening Effort (ACALES). Participants will be equipped with an EEG cap. A continuous EEG will be recorded while participants are performing the LET. Based on the EEG data the alpha power will be analysed offline afterwards.

Secondary Outcome Measures

  1. EEG alpha power measured during Listening Span Task (LST) [10 weeks]

    During the LST experiment EEG data will be recorded while participants perform the Working Memory Test. Participants will be equipped with an EEG cap. A continuous EEG will be recorded while participants are performing the LST. Based on the EEG data the alpha power will be analysed offline afterwards.

  2. Listening effort (ACALES) measured during Listening Effort Task (LET) [10 weeks]

    The speech material of the ACALES is based on the German OLSA sentence matrix test (Wagener, 1999). All sentences are syntactically identical and consist of five word categories (name, verb, number, adjective, and object, e.g., "Peter kauft fünf rote Blumen" [engl. "Peter buys five red flowers"]). Each trial consists of a sequence of three (different) sentences, after which participants are asked to rate their perceived listening effort on a scale via touch screen. The scale ranges from 1 (no effort) to 13 (extreme effort) based on the ACALES (Krüger, 2017). These values (effort scaling units - ESCU) constitute the subjective behavioral data regarding the personal experience of listening effort. The ACALES is part of the LET experiment and is therefore combined with EEG recordings (see outcome 1).

  3. Working memory measured with Listening Span Task (LST) [10 weeks]

    The material in the LST task is taken from the Basler sentence test (Tschopp, 2001). Half of the sentences are high predictable sentences (HP) and the other half were low predictable (LP) sentences. The participants' task is to repeat the sentence they hear and remember the last word of each sentence. After four sentences, the participants is asked to recall the final words of the last four sentences. The experimenter scores the number of correctly repeated final words after each sentence (words recognized) as well as the number of correctly recalled final words (words remembered). Based on this, a relative memory score is calculated. The Working Memory Test is part of the LST and is therefore combined with EEG recordings (see outcome 2).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Experienced (minimum use duration 6 months)

  • Adult (minimum age: 18 years) hearing aid users,

  • Symmetrical hearing loss (difference between ears <= 10 dB for 1kHz-6kHz),

  • Sensorineural hearing loss,

  • Air Conduction - bone conduction gap <= 10 dB,

  • Written and spoken German,

  • Ability to understand instruction,

  • Ability to describe listening experiences,

  • Ability to attend to the appointments,

  • Healthy outer ear (without previous surgical proce-dures),

  • Hearing loss within the fitting ranges of the investiga-tional product,

  • Informed consent as documented by signature.

Exclusion Criteria:
  • Clinical contraindications deformity of the ear (closed ear canal or absence of pinna),

  • Known hypersensitivity or allergy,

  • Not willing to wear the hearing aid,

  • Fluctuating hearing that could influence the results,

  • Limited mobility and not in the position to attend all appointments,

  • Inability to produce a reliable hearing test result,

  • Massively limited dexterity,

  • Known psychological problems,

  • Known central hearing disorders.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Sonova AG
  • Hoerzentrum Oldenburg

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sonova AG
ClinicalTrials.gov Identifier:
NCT06049199
Other Study ID Numbers:
  • 15063
First Posted:
Sep 22, 2023
Last Update Posted:
Sep 22, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Sep 22, 2023